 Given the high degree of efficacy of the docetaxelcapecitabine combination, but the significant toxicity observed with 1,250 mgm2 bid capecitabine schedule, as well as the promising efficacy and safety observed with weekly paclitaxelcapecitabine in the phase I study by Uhlmann et al 27, we choose weekly paclitaxel for combination regimen with capecitabine. Practically, our study regimen is capecitabine plus paclitaxelXT combination chemotherapy. 